No Data
Everbright: Import substitution is expected to accelerate, pay attention to the rising market share of domestic surgical robots.
Everbright stated that the import substitution is expected to accelerate, paying attention to the rise in market share of domestic surgical robots.
China Securities Co.,Ltd.: It is recommended to focus on the new growth and integration opportunities in the Industry.
China Securities Co.,Ltd. remains bullish on high-quality Innovative Drugs companies in 2025 and actively focuses on cutting-edge technologies in pharmaceuticals and medical devices.
Investors who bought high-level pharmaceutical Funds have hope! More than 80% of products achieved positive returns in the first quarter, and recovering losses is promising.
① A total of 264 medical Funds had positive returns in the first quarter of this year, accounting for over 80%, with many Funds achieving returns exceeding 15% this year. ② The net value of medical Funds established in 2020 and 2021 is currently being repaired, and investors who entered at high levels are expected to break even.
VENUS MEDTECH-B (02500.HK) is projected to incur a loss of 0.714 billion yuan for the year 2024.
Gelonghui reported on March 28 that VENUS MEDTECH-B (02500.HK) announced its annual performance for the year ending December 31, 2024. The group's revenue was 0.471 billion RMB, a decrease of 4.2% year-on-year; the loss attributable to shareholders of the parent company was 0.714 billion RMB, compared to a loss of 0.704 billion RMB in the same period of 2023, with a basic loss per share of 1.63 RMB.
VENUS MEDTECH-B (02500) released its annual performance, achieving a revenue of 0.471 billion yuan, with several important milestones reached in Global clinical research projects.
VENUS MEDTECH-B (02500) announced its annual performance for the year ending December 31, 2024, during which the group achieved...
Express News | Venus Medtech Hangzhou FY Capex RMB 41.6 Million
